WO1996013226A1 - Method for the treatment of periodontal disease and a pharmaceutical composition useful in said method - Google Patents
Method for the treatment of periodontal disease and a pharmaceutical composition useful in said method Download PDFInfo
- Publication number
- WO1996013226A1 WO1996013226A1 PCT/US1995/013989 US9513989W WO9613226A1 WO 1996013226 A1 WO1996013226 A1 WO 1996013226A1 US 9513989 W US9513989 W US 9513989W WO 9613226 A1 WO9613226 A1 WO 9613226A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- growth factor
- nsaid
- dental tissue
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
Abstract
A method for the treatment of periodontitis and a pharmaceutical composition for use in the method. According to a preferred embodiment, the method comprises administering to a mammal afflicted with periodontitis a therapeutically effective amount of a pharmaceutical composition comprising a polypeptide growth factor and an NSAID to regenerate dental tissue in the mammal afflicted with periodontitis and, thereafter, administering to the mammal a therapeutically effective amount of an NSAID to prevent resorption of the newly regenerated dental tissue.
Description
METHOD FOR THE TREATMENT OF PERIODONTAL DISEASE AND A PHARMACEUTICAL COMPOSITION USEFUL IN SAID METHOD
FIELD OF THE INVENTION
The present invention relates generally to the treatment of periodontal disease and more particularly to a novel method for treating periodontal disease and to a pharmaceutical composition useful in said method.
BACKGROUND OF THE INVENTION Periodontal disease, which includes any abnormality, whether inflammatory or degenerative, of tissue around a tooth, is very common worldwide. For example, the World Health Organization estimated some years ago that, even if there were no new periodontal disease, it would still take 45 years to treat those people already afflicted therewith. In addition, the Journal of Public Health Dentistry concluded in 1985 that "more than two out of three patients were affected by periodontal disease." Moos, W.F., Medical Marketing & Media, 52-54 (1985). Two common types of periodontal disease are chronic gingivitis (i.e., an inflammation of the gingiva or gums) and chronic destructive periodontitis (i.e., a disease of the connective tissue which attaches a tooth to the alveolar bone, which disease results in alveolar bone resorption, increasing mobility of the tooth and, ultimately, tooth loss). Clinically, chronic gingivitis (hereinafter simply "gingivitis") and chronic destructive periodontitis (hereinafter simply "periodontitis") actually represent varying stages of periodontal disease, with gingivitis, if uncontrolled, progressing into periodontitis.
It is known that periodontal disease is caused, at least initially, by the accumulation of bacterial plaque on the teeth and under the gingiva of a patient, said accumulation of plaque triggering an inflammatory and immunological response in the patient. Nevertheless, although the cause of periodontal disease is known, progress in the prevention and treatment thereof has been limited. Preventive techniques have relied heavily on establishing and maintaining good oral hygiene including mechanically and/or chemically preventing the accumulation of bacterial plaque on the teeth and under the gingiva. Therapies directed at treating existing advanced periodontal disease have primarily been directed at
expensive and ongoing medical procedures, such as periodontal surgery, which in many cases must be carried out often over an indefinite period of time and which have not been clearly shown to be effective in arresting alveolar bone loss and preserving teeth. Because of the initial inflammatory aspect of periodontal disease, a number of researchers have recently investigated the use of certain anti- inflammatory agents as possible therapies for treating gingivitis.
In U.S. Patent No. 5,149,691 , inventors Rutherford et al., which issued September 22, 1992 and which is incorporated herein by reference, there is described a method purported to be useful for the regeneration of tissue and the treatment of periodontal disease which is comprised of applying to an afflicted tissue a pharmaceutically effective amount of a composition comprised of platelet- derived growth factor and dexamethasone.
One problem noted by the present inventor with the aforementioned Rutherford et al. method is that the regeneration of dental tissue achieved thereby tends to be transient, the regenerated dental tissue typically suffering resorption by the alveolar bone once administration of the pharmaceutical composition ceases. Another potential problem noted by the present inventor with the foregoing Rutherford et al. method is presented by the use of dexamethasone, which is a steroid and may cause unwanted side-effects. In U.S. Patent No. 5, 190,981 , inventor Wechter, which issued March 2, 1993 and which is incorporated herein by reference, there is described a method purported to be useful in reducing alveolar bone loss associated with periodontal disease and a composition useful in the method. The method comprises applying to buccal membranes a therapeutically effective quantity of an enantiomer, generally an S enantiomer, of a nonsteroidal anti-inflammatory drug, such as (S)- flurbiprofen or (S)-ketoprofen. The composition is a formulation which is a toothpaste or which is a mouthwash.
In U.S. Patent No. 4,933,172, inventors Clark, Jr. et al., which issued June 12, 1990 and which is incorporated herein by reference, there is disclosed a method and composition purported to be useful in treating destructive periodontal disease. More specifically, 2-(2,6-dichloro-3-methylphenylamino)benzoic acid and
it: physiologically acceptable salts are said to be effective in inhibiting the conversion of gingivitis to periodontitis and thus are said to be useful in treating destructive periodontal disease. The patent discloses applying the therapeutic agent directly to the gingival tissue in a topically administrable pharmaceutical composition or releasing the therapeutic agent in the buccal cavity for contact with the gingival tissue through the fluid motion present in the mouth.
In U.S. Patent No. 4,906,670, inventors Higashi et al., which issued March 6, 1990 and which is incorporated herein by reference, there is disclosed a pharmaceutical composition purported to be useful for treatment of periodontal diseases which comprises one or more active ingredients effective for the treatment of periodontal diseases, characterized in that said active ingredient or ingredients are dispersed in collagen.
Other patents and publications of interest include the following, all of which are incorporated herein by reference: U.S. Patent No. 4,996,209, inventor Aoki, issued February 26, 1991; U.S. Patent No. 4,975,271, inventors Dunn et al., issued December 4, 1990; U.S. Patent No. 4,927,854, inventors Sunshine et al., issued May 22, 1990; U.S. Patent No. 4,569,837, inventors Suzuki et al., issued February 11 , 1986; PCT Application No. PCT/US90/04623, published March 7, 1991; PCT Application No. PCT/US88/03956, published June 1 , 1989; PCT Application No. PCT/US87/00059, published August 13, 1987; European Patent Application No. 84305661.5, published April 17, 1985; Becker et al., "A Comparison of ePTFE Membranes Alone or in Combination with Platelet-Derived Growth Factors and Insulin-Like Growth Factor-I or Demineralized Freeze-Dried Bone in Promoting Bone Formation Around Immediate Extraction Socket Implants," J. Periodontol, 63:929-940 (1992); Jeffcoat et al., "Flurbiprofen treatment of human periodontitis: effect on alveolar bone height and metabolism," J. Periodont. Res., 23:381-385 (1988); and Jamali et al., "Stereoselective Pharmacokinetics of Flurbiprofen in Humans and Rats," Journal of Pharmaceutical Sciences, Vol. 77, No. 8, pp. 666- 669 (August 1988).
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a new method for treating periodontal disease in general and periodontitis in particular.
According to one aspect of the invention, there is described a method for regenerating mammalian dental tissue, such as that afflicted with periodontitis (e.g., gum tissue, periodontal ligature, etc.), said method comprising the step of administering to the mammalian dental tissue a therapeutically effective amount of a pharmaceutical composition comprising a growth factor and an NSAID. According to a preferred embodiment of the invention, the growth factor of the present pharmaceutical composition is a polypeptide (i.e., proteinaceous) growth factor.
The expression "polypeptide growth factor," as used in the present specification and claims, refers to a class of natural biological mediators that regulate the proliferation, differentiation, motility and matrix synthesis of nearly all cell types. It is also believed that such factors play important roles in soft and hard tissue repair. Examples of polypeptide growth factors include, but are not limited to, platelet-derived growth factor (PDGF), insulin-like growth factor-1 (IGF-1 ), transforming growth factor alpha (TGF-σ), cartilage-derived growth factor (CDGF) and growth hormones (such as human growth hormone). The polypeptide growth factors of the present invention may be naturally occurring polypeptide growth factors, polypeptide growth factors obtained by recombinant means expressed in either eukaryotic or prokaryotic systems, biologically active mutant forms of naturally occurring polypeptide growth factors, biologically active fragments or subunits of naturally occurring polypeptide growth factors, or biologically active mutants of biologically active fragments or subunits of naturally occurring polypeptide growth factors.
The term "NSAID," as used in the present specification and claims, is defined to mean a non-steroidal, anti-inflammatory drug and is to be contrasted with steroidal, anti-inflammatory drugs. Examples of NSAID's, as presently defined, include, but are not limited to acetaminophen, ketorolac, aspirin and the class of aryl propionic acids, such as ketoprofen, etodolac, flurbiprofen, carprofen,
ibuprofen, naproxen, indoprofen, pierprofen, pranoprofen, microprofen, thiaoxa and aminoprofen. In those instances in which the NSAID is chiral, the NSAID is preferably in the form of a substantially pure, pharmacologically active enantiomer. In most instances, the pharmacologically active enantiomer is the S(+) enantiomer. According to another aspect of the invention, there is described a method of regenerating mammalian dental tissue afflicted with periodontitis and, over a subsequent period of time, preventing the resorption of the regenerated mammalian dental tissue, said method comprising the steps of (a) administering to the afflicted mammalian dental tissue a therapeutically effective amount of a pharmaceutical composition comprising an NSAID and a growth factor, for example, a polypeptide growth factor; and (b) then, administering to the regenerated mammalian dental tissue a therapeutically effective amount of an NSAID to prevent the resorption of the regenerated mammalian dental tissue over said subsequent period of time.
The present invention is also directed to a pharmaceutical composition useful in regenerating mammalian dental tissue, such as that afflicted with periodontitis, the pharmaceutical composition comprising an NSAID and a growth factor, for example, a polypeptide growth factor. As can readily be appreciated, because it includes an NSAID, the aforementioned pharmaceutical composition is also useful in reducing inflamed mammalian dental tissue, such as that afflicted with gingivitis.
Additional objects, aspects, features and advantages, of the present invention will be set forth in part in the description of preferred embodiments which follows, and in part will be obvious from the description of preferred embodiments or may be learned by practice of the invention. The preferred embodiments will be described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that other embodiments may be utilized and that structural changes may be made without departing from the scope of the invention. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is best defined by the appended claims.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The present invention is directed at a new method of treating periodontitis and at a new pharmaceutical composition useful in said method (it being understood that the present method and pharmaceutical composition could also be used to treat gingivitis).
According to a preferred embodiment, the method of the present invention comprises the following steps: First, a pharmaceutical composition comprising a polypeptide growth factor and an NSAID is administered to a mammal suffering from periodontitis, the pharmaceutical composition being administered in a therapeutically effective amount to cause the regeneration and repair of afflicted dental tissue in the mammal. Then, an NSAID is administered to the afflicted mammal, the NSAID being administered in a therapeutically effective amount to prevent the repaired and regenerated dental tissue from thereafter being lost, for example, by alveolar bone resorption. It is presently envisioned, although not required, that the aforementioned first step will be performed by a dentist or similar dental care provider by directly applying to the affected dental tissue a composition of the polypeptide growth factor and the NSAID in a pharmaceutically acceptable carrier for topical administration. Examples of pharmaceutically acceptable carriers are ointments, creams, gels, matrices and liquids of the type described in U.S. Patent No. 5,149,691. In much the same manner as set forth in U.S. Patent No. 5,149,691 , combinations of the aforementioned polypeptide growth factors, such as PDGF+IGF-1 or PDGF+TGFσ, may be used instead of a single polypeptide growth factor to achieve greater healing of the injured tissue. Similarly, combinations of NSAID's may be used instead of a single NSAID. As indicated above, where the NSAID is chiral, it is preferable to include only the pharmacologically active enantiomer, which is typically the S(+) enantiomer. Flavoring or buffering agents may additionally be included in the above-described pharmaceutical composition to counter the unpleasant effects associated with the topical administration of NSAID's. The range of concentration for the polypeptide growth factor in the subject pharmaceutical composition can be approximately 10 mg/ml to 1 g/ml, and the
range of concentration for the NSAID in the subject pharmaceutical composition can be approximately 50 mg/ml to 50 g/ml.
It is also presently envisioned, although not required, that the aforementioned second step of preserving the repaired and regenerated dental tissue will be performed by the patient by directly applying to the affected dental tissue a composition of an NSAID in a pharmaceutically acceptable formulation. Examples of pharmaceutically acceptable formulations are toothpastes and mouthwashes of the type described in U.S. Patent No. 5,190,981 , as well as gels of the type typically applied using a dental impression-type tray. Examples of suitable compositions comprising an NSAID in a toothpaste or mouthwash formulation are also described in U.S. Patent No. 5,190,981. Such compositions preferably also include a cavity preventive agent, as well as a flavoring or buffering agent. It is presently anticipated that the NSAID-containing toothpaste or mouthwash will be administered by the patient twice daily over an indefinite period of time, i.e., the lifetime of the patient. Long-term use of the NSAID-containing toothpaste or mouthwash is presently deemed to be advisable to prevent the subsequent resorption of the newly regenerated dental tissue.
The embodiments of the present invention described above are intended to be merely exemplary and those skilled in the art shall be able to make numerous variations and modifications to them without departing from the spirit of the present invention. All such variations and modifications are intended to be within the scope of the present invention as defined in the appended claims.
Claims
1. A method of regenerating mammalian dental tissue, said method comprising the step of administering to said mammalian dental tissue a therapeutically effective amount of a pharmaceutical composition comprising a growth factor and an NSAID.
2. The method as claimed in claim 1 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
3. The method as claimed in claim 1 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable carrier for topical administration and wherein said administering step comprises topically administering said pharmaceutical composition.
4. The method as claimed in claim 1 wherein said growth factor is a polypeptide growth factor.
5. The method as claimed in claim 4 wherein said polypeptide growth factor is selected from the group consisting of PDGF, IGF-1 , TGFσ and CDGF and wherein said NSAID is selected from the group consisting of acetaminophen, aspirin and aryl propionic acids.
6. A method of regenerating mammalian dental tissue afflicted with periodontitis and, over a subsequent period of time, preventing the resorption of the regenerated mammalian dental tissue, said method comprising the steps of:
(a) administering to the afflicted mammalian dental tissue a therapeutically effective amount of a pharmaceutical composition comprising a growth factor and an NSAID; and
(b) then, administering to the regenerated mammalian dental tissue a therapeutically effective amount of an NSAID to prevent the resorption of the regenerated mammalian dental tissue over said subsequent period of time.
7. The method as claimed in claim 6 wherein said pharmaceutical composition comprising a growth factor and an NSAID further comprises a pharmaceutically acceptable carrier.
8. The method as claimed in claim 6 wherein said NSAID administered in step (b) is administered in a pharmaceutically acceptable formulation.
9. The method as claimed in claim 8 wherein said pharmaceutically acceptable formulation is selected from the group consisting of pharmaceutically acceptable toothpaste formulations and pharmaceutically acceptable mouthwash formulations.
10. The method as claimed in claim 9 wherein said pharmaceutically acceptable formulation is a pharmaceutically acceptable toothpaste formulation, said pharmaceutically acceptable toothpaste formulation further comprising a flavoring agent and a cavity preventive agent.
11. The method as claimed in claim 6 wherein said growth factor is a polypeptide growth factor.
12. A method of treating periodontal disease in a mammal afflicted therewith, said method comprising the steps of:
(a) administering to the afflicted mammal a therapeutically effective amount of a pharmaceutical composition comprising a growth factor and an NSAID; and
(b) then, administering to the afflicted mammal a therapeutically effective amount of an NSAID.
13. The method as claimed in claim 12 wherein said growth factor is a polypeptide growth factor.
14. A pharmaceutical composition useful in regenerating mammalian dental tissue, said pharmaceutical composition comprising:
(a) a growth factor; and
(b) an NSAID.
15. The pharmaceutical composition as claimed in claim 14 wherein said growth factor is a polypeptide growth factor.
16. The pharmaceutical composition as claimed in claim 15 wherein said polypeptide growth factor is selected from the group consisting of PDGF, IGF-1, TGFσ and CDGF.
17. The pharmaceutical composition as claimed in claim 16 wherein said polypeptide growth factor is PDGF.
18. The pharmaceutical composition as claimed in claim 17 further comprising a second polypeptide growth factor selected from the group consisting of IGF-1 and TGFσ.
19. The pharmaceutical composition as claimed in claim 14 wherein said NSAID is selected from the group consisting of acetaminophen, aspirin, ketorolac and aryl propionic acids.
20. The pharmaceutical composition as claimed in claim 19 wherein said NSAID is an aryl propionic acid.
21. The pharmaceutical composition as claimed in claim 20 wherein said NSAID is selected from the group consisting of ketoprofen, etodolac, flurbiprofen, carprofen, ibuprofen, naproxen, indoprofen, pierprofen, pranoprofen, microprofen, thiaoxa and aminoprofen.
22. The pharmaceutical composition as claimed in claim 21 wherein said NSAID is a substantially pure, pharmacologically active enantiomer.
23. The pharmaceutical composition as claimed in claim 22 wherein said
NSAID is the S enantiomer.
24. The pharmaceutical composition as claimed in claim 19 wherein said
NSAID is selected from the group consisting of flurbiprofen, ketoprofen and ketorolac.
25. The pharmaceutical composition as claimed in claim 14 further comprising a pharmaceutically acceptable carrier.
26. The pharmaceutical composition as claimed in claim 14 further comprising a pharmaceutically acceptable carrier for topical administration.
27. A method of regenerating mammalian dental tissue afflicted with periodontitis and, over a subsequent period of time, preventing the resorption of the regenerated mammalian dental tissue, said method comprising the steps of:
(a) administering to the afflicted mammalian dental tissue a therapeutically effective amount of a growth factor; and
(b) administering to the regenerated mammalian dental tissue a therapeutically effective amount of an NSAID to prevent the resorption of the regenerated mammalian dental tissue over said subsequent period of time.
28. The method as claimed in claim 27 wherein steps (a) and (b) are performed simultaneously.
29. The method as claimed in claim 27 wherein step (b) is performed after step (a).
30. The method as claimed in claim 27 wherein said growth factor is a polypeptide growth factor.
31. A kit for use in treating periodontal disease, said kit comprising:
(a) a first vial containing an NSAID; and
(b) a second vial containing a growth factor.
32. The kit as claimed in claim 31 wherein said growth factor is a polypeptide growth factor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU41375/96A AU4137596A (en) | 1994-10-31 | 1995-10-30 | Method for the treatment of periodontal disease and a pharmaceutical composition useful in said method |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33253294A | 1994-10-31 | 1994-10-31 | |
| US08/332,532 | 1994-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996013226A1 true WO1996013226A1 (en) | 1996-05-09 |
Family
ID=23298643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1995/013989 WO1996013226A1 (en) | 1994-10-31 | 1995-10-30 | Method for the treatment of periodontal disease and a pharmaceutical composition useful in said method |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU4137596A (en) |
| WO (1) | WO1996013226A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0821970A1 (en) * | 1996-08-02 | 1998-02-04 | Edward Henri Charles Verhaeren | Carrier composition for influencing the tight junction permeability |
| EP2322226A3 (en) * | 1999-07-21 | 2011-08-17 | Omeros Corporation | Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| US8870954B2 (en) | 2008-09-09 | 2014-10-28 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
| US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| US9545377B2 (en) | 2004-10-14 | 2017-01-17 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
| US9642891B2 (en) | 2006-06-30 | 2017-05-09 | Biomimetic Therapeutics, Llc | Compositions and methods for treating rotator cuff injuries |
| US10258566B2 (en) | 2004-10-14 | 2019-04-16 | Biomimetic Therapeutics, Llc | Compositions and methods for treating bone |
| US11235030B2 (en) | 2010-02-22 | 2022-02-01 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919939A (en) * | 1986-04-29 | 1990-04-24 | Pharmetrix Corporation | Periodontal disease treatment system |
| US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US5447725A (en) * | 1993-06-11 | 1995-09-05 | The Procter & Gamble Company | Methods for aiding periodontal tissue regeneration |
-
1995
- 1995-10-30 AU AU41375/96A patent/AU4137596A/en not_active Abandoned
- 1995-10-30 WO PCT/US1995/013989 patent/WO1996013226A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919939A (en) * | 1986-04-29 | 1990-04-24 | Pharmetrix Corporation | Periodontal disease treatment system |
| US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US5447725A (en) * | 1993-06-11 | 1995-09-05 | The Procter & Gamble Company | Methods for aiding periodontal tissue regeneration |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0821970A1 (en) * | 1996-08-02 | 1998-02-04 | Edward Henri Charles Verhaeren | Carrier composition for influencing the tight junction permeability |
| WO1998005359A1 (en) * | 1996-08-02 | 1998-02-12 | Ghyssaert, Joris, Rosa, Michael | Carrier composition for influencing the tight junction permeability |
| EP2322226A3 (en) * | 1999-07-21 | 2011-08-17 | Omeros Corporation | Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| US11571497B2 (en) | 2004-10-14 | 2023-02-07 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
| US11364325B2 (en) | 2004-10-14 | 2022-06-21 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
| US9545377B2 (en) | 2004-10-14 | 2017-01-17 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
| US11318230B2 (en) | 2004-10-14 | 2022-05-03 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods of use thereof |
| US10258566B2 (en) | 2004-10-14 | 2019-04-16 | Biomimetic Therapeutics, Llc | Compositions and methods for treating bone |
| US11058801B2 (en) | 2006-06-30 | 2021-07-13 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| US10456450B2 (en) | 2006-06-30 | 2019-10-29 | Biomimetic Therapeutics, Llc | Compositions and methods for treating rotator cuff injuries |
| US9642891B2 (en) | 2006-06-30 | 2017-05-09 | Biomimetic Therapeutics, Llc | Compositions and methods for treating rotator cuff injuries |
| US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| US11135341B2 (en) | 2008-09-09 | 2021-10-05 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor composition and methods for the treatment of tendon and ligament injuries |
| US8870954B2 (en) | 2008-09-09 | 2014-10-28 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
| US11235030B2 (en) | 2010-02-22 | 2022-02-01 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
Also Published As
| Publication number | Publication date |
|---|---|
| AU4137596A (en) | 1996-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5902110A (en) | Bone regeneration | |
| Hildebrandt et al. | Maintaining mutans streptococci suppression: with xylitol chewing gum | |
| US5939047A (en) | Local delivery of chemotherapeutic agents for treatment of periodontal disease | |
| EP0137668B2 (en) | Ibuprofen, flurbiprofen and their therapeutic use | |
| US4097604A (en) | Method of treating and controlling gingivitis | |
| Hirooka | The biologic concept for the use of enamel matrix protein: true periodontal regeneration. | |
| Henry et al. | Tissue regeneration in bony defects adjacent to immediately loaded titanium implants placed into extraction sockets: a study in dogs. | |
| US4215144A (en) | Method of treating and controlling gingivitis | |
| Rasperini et al. | The soft tissue wall technique for the regenerative treatment of non-contained infrabony defects: a case series | |
| US4214006A (en) | Mouthwash and method for preventing and removing dental plaque | |
| Castioni et al. | Current status in oral fluoride pharmacokinetics and implications for the prophylaxis against dental caries | |
| GINGIVITIS | Treatment of plaque-induced gingivitis, chronic periodontitis, and other clinical conditions | |
| WO1996013226A1 (en) | Method for the treatment of periodontal disease and a pharmaceutical composition useful in said method | |
| Eeckhout et al. | A randomized controlled trial evaluating hyaluronic acid gel as wound healing agent in alveolar ridge preservation | |
| WO1991002512A1 (en) | Buccal composition containing s(+) flurbiprofen or ketoprofen | |
| US4985235A (en) | Treatment of periodontoclasia with retinoic acid | |
| Taib et al. | Amlodipine-induced gingival overgrowth: a case report | |
| EP3914258B1 (en) | A composition for the treatment of periodontitis and regeneration of interdental papilla | |
| JPH0645535B2 (en) | Composition for treating alveolar bone metabolism | |
| EP0266354B1 (en) | Composition for preparing a medicament for topical treatment of paradentium diseases | |
| AU614643B2 (en) | Treatment of periodontoclasia with retinoic acid | |
| JPH09291018A (en) | Composition for oral cavity | |
| Chee | Peri-implant management of patients with aggressive periodontitis | |
| Wijaksana et al. | Fibrin-assisted soft tissue promotion (FASTP) as a simple root coverage technique: A case report | |
| Nozawa et al. | Connective Tissue--Bone Onlay Graft with Enamel Matrix Derivative for Treatment of Gingival Recession: A Case Report. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase |